Novation’s semi-annual Drug Price Forecast is designed to offer information and support resources to aid in the development of annual drug budget projections. The report summary includes the following key points:
• Novation projects an estimated weighted drug price inflation of 1.36 percent through June 2013, driven by continued developed of generic alternatives to brand-name pharmaceuticals.
• Contract products will see a 0.24 percent price change, while non-contract pharmaceuticals will see a 2.66 percent price change.
• Antineoplastic agents, serums and hematopoietic agents are the top three therapeutic classes, making up 20.6 percent, 8.7 percent and 8.6 percent of aggregate acute purchases.
• Other top therapeutic classes include disease modifying anti-rheumatic agents, heparins, hemostatics and vaccines.
To view Novation’s Drug Price Forecast Summary Report, Winter 2012 in full, click here.
Related Articles on Supply Chain:
Provista Names Dino Eliopoulos CFO
Spencer Hospital, Surgery Center Approves $306k Lease With Stryker Endoscopy
AdvaMed’s President Issues Statement on ‘Ensuring Safe Medical Devices for Patients’ Legislation
